| scholarly article | Q13442814 |
| P50 | author | Vanessa L. Gates | Q39378569 |
| Riad Salem | Q45736667 | ||
| Ahsun Riaz | Q63249344 | ||
| Reed A. Omary | Q86839285 | ||
| P2093 | author name string | Laura M Kulik | |
| Al B Benson | |||
| Robert J Lewandowski | |||
| Robert K Ryu | |||
| Frank H Miller | |||
| Ed Wang | |||
| Kent T Sato | |||
| Mary F Mulcahy | |||
| Michael Abecassis | |||
| Ramona Gupta | |||
| Talia Baker | |||
| Ritu Nayar | |||
| Paul Nikolaidis | |||
| Khairuddin Memon | |||
| P2860 | cites work | The Measurement of Observer Agreement for Categorical Data | Q26778373 |
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Yttrium-90 microspheres: radiation therapy for unresectable liver cancer | Q28204605 | ||
| The meaning and use of the area under a receiver operating characteristic (ROC) curve | Q29547182 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Management of hepatocellular carcinoma | Q29616230 | ||
| Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver | Q29616866 | ||
| Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial | Q29617955 | ||
| Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma | Q29617957 | ||
| Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis | Q29619508 | ||
| Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study | Q33631372 | ||
| Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization | Q34065098 | ||
| A method of comparing the areas under receiver operating characteristic curves derived from the same cases | Q34272510 | ||
| Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. | Q34363246 | ||
| Hepatocellular carcinoma and hepatitis C in the United States | Q34528514 | ||
| Chemoembolization for hepatocellular carcinoma | Q34552214 | ||
| Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. | Q34552875 | ||
| Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. | Q34579127 | ||
| Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes | Q35004090 | ||
| Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma | Q35051942 | ||
| The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma | Q35648702 | ||
| Measures of response: RECIST, WHO, and new alternatives | Q36531372 | ||
| Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. | Q36573194 | ||
| Design and endpoints of clinical trials in hepatocellular carcinoma. | Q37162908 | ||
| Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma | Q39926325 | ||
| Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? | Q46178855 | ||
| Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients | Q46902655 | ||
| Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria | Q47378801 | ||
| Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. | Q51066211 | ||
| Diagnosis and Treatment of Hepatocellular Carcinoma | Q56172242 | ||
| Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres | Q63198750 | ||
| Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization | Q79743588 | ||
| Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging | Q81700730 | ||
| A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization | Q84121312 | ||
| Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival | Q84634948 | ||
| P433 | issue | 4 | |
| P921 | main subject | World Health Organization | Q7817 |
| hepatocellular carcinoma | Q1148337 | ||
| P304 | page(s) | 695-704 | |
| P577 | publication date | 2010-10-23 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation | |
| P478 | volume | 54 |
| Q92785243 | A Pretreatment CT Model Predicts Survival Following Chemolipiodolization in Patients With Hepatocellular Carcinoma |
| Q28831507 | A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis |
| Q35894925 | Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis |
| Q48156557 | Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma. |
| Q38265114 | Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI. |
| Q37238192 | Chemoembolization and radioembolization for hepatocellular carcinoma. |
| Q40091767 | Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection. |
| Q41859517 | Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma |
| Q89509359 | Contralateral Liver Hypertrophy and Oncological Outcome Following Radioembolization with 90Y-Microspheres: A Systematic Review |
| Q87354841 | Contrast-enhanced ultrasound after devascularisation of neuroendocrine liver metastases: functional and morphological evaluation |
| Q57782407 | Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation |
| Q44481786 | Diagnosis of and therapy for hepatocellular carcinoma |
| Q58702085 | Dynamic Three-Dimensional Contrast-Enhanced Ultrasound to Predict Therapeutic Response of Radiofrequency Ablation in Hepatocellular Carcinoma: Preliminary Findings |
| Q35691040 | Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. |
| Q36832118 | Evaluation of cancer treatment in the abdomen: Trends and advances |
| Q96231885 | Evaluation of liver tumour response by imaging |
| Q38265024 | Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. |
| Q24194024 | External beam radiotherapy for unresectable hepatocellular carcinoma |
| Q36299237 | External beam radiotherapy for unresectable hepatocellular carcinoma. |
| Q46109448 | Feasibility of Using Volumetric Contrast-Enhanced Ultrasound with a 3-D Transducer to Evaluate Therapeutic Response after Targeted Therapy in Rabbit Hepatic VX2 Carcinoma |
| Q92377286 | From a Philosophical Framework to a Valid Prognostic Staging System of the New "Comprehensive Assessment" for Transplantable Hepatocellular Carcinoma |
| Q38716483 | Hepatic imaging following intra-arterial embolotherapy |
| Q35537007 | Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers |
| Q37680183 | Imaging of hepatocellular carcinoma and image guided therapies - how we do it. |
| Q38984450 | In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? |
| Q34253205 | Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy |
| Q37143017 | Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma |
| Q39349682 | Interventional Oncology Service Development |
| Q39041266 | Intra-arterial therapies for liver cancer: assessing tumor response |
| Q35203257 | Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma |
| Q34681150 | Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma |
| Q55364224 | Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review. |
| Q92379362 | Prediction of hepatocellular carcinoma response to 90Yttrium radioembolization using volumetric ADC histogram quantification: preliminary results |
| Q36481071 | Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. |
| Q48193183 | Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses |
| Q35815482 | Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes |
| Q35564038 | Radioembolization for primary and metastatic liver cancer. |
| Q35154103 | Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times |
| Q38080022 | Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies |
| Q34680081 | Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis |
| Q42237455 | Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. |
| Q37396802 | Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib |
| Q53167805 | Radiological-pathological correlation study of hepatocellular carcinoma undergoing local chemoradiotherapy and surgery. |
| Q37253841 | Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis |
| Q35111887 | Research reporting standards for radioembolization of hepatic malignancies. |
| Q36773155 | Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome |
| Q90008768 | Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort |
| Q37348887 | Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. |
| Q43961233 | Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres |
| Q53548617 | TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. |
| Q58616102 | The physics of radioembolization |
| Q36104314 | Transcatheter intraarterial therapies: rationale and overview |
| Q38236876 | Treatment of intermediate-stage hepatocellular carcinoma |
| Q50223119 | Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL? |
| Q26743603 | Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review |
| Q24186130 | Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma |
| Q24194017 | Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma |
Search more.